finance.yahoo.com

Arbutus receives about $178M from Moderna settlement while Moderna builds mRNA pipeline

Arbutus Biopharma logoArbutus Biopharma
Sig2.68Sen+3.35Env0.00Soc0.00Gov+0.95
Moderna logoModerna
Sig3.65Sen-2.40Env0.00Soc0.00Gov-1.60

Arbutus Biopharma received about $178 million from Moderna, its share of a $950 million noncontingent settlement paid through licensee Genevant Sciences. Moderna reported $960 million operating expenses, including $651 million R&D, and a $782 million net loss, while holding about $6.9 billion in cash and investments before remitting the settlement in July 2026. Arbutus’s quarterly net income and low operating costs are highlighted alongside Moderna’s expanded late-stage mRNA pipeline and shifting institutional ownership.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro